Development of Three Ebola Vaccines Accelerates Amid Outbreak Concerns
Three Ebola vaccines in development amid growing outbreak fears
The Bbc
Image: The Bbc
Three new Ebola vaccines are under development in response to a growing outbreak in the Democratic Republic of the Congo (DR Congo) that has already claimed nearly 250 lives. The International Aids Vaccine Initiative, Moderna, and the University of Oxford are leading efforts, with clinical trials expected soon.
- 01The outbreak in DR Congo has over 1,000 suspected cases and nine confirmed cases in Uganda.
- 02The International Aids Vaccine Initiative is modifying an existing Zaire Ebola vaccine for the Bundibugyo species, which lacks an approved vaccine.
- 03Moderna is utilizing its mRNA technology to develop a vaccine, aiming for clinical trials in two to three months.
- 04The Coalition for Epidemic Preparedness Innovations is funding the research, emphasizing the urgency of vaccine development.
- 05Dr. Tedros Adhanom Ghebreyesus of the WHO highlighted the potential of a Bundibugyo vaccine to control the current epidemic.
Advertisement
In-Article Ad
In light of a severe Ebola outbreak in the Democratic Republic of the Congo (DR Congo), three vaccines are being developed to combat the Bundibugyo species, which has already resulted in nearly 250 deaths. The International Aids Vaccine Initiative (IAVI) is working on a modified version of the Zaire Ebola vaccine, which has shown promising results in monkey trials, although it may take seven to nine months to enter clinical trials. Moderna is also developing a vaccine using mRNA technology, aiming for trials within two to three months. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding these efforts, stressing the urgency due to over 1,000 suspected cases in DR Congo and confirmed cases in Uganda. Health officials are alarmed by the rapid spread of the virus, which could lead to an outbreak as severe as the 2014-2016 West Africa crisis. The vaccines are designed to train the immune system to recognize the Bundibugyo glycoprotein, critical for mounting an effective response against the virus.
Advertisement
In-Article Ad
The outbreak poses a significant public health threat in the DR Congo and surrounding regions, necessitating rapid vaccine development.
Advertisement
In-Article Ad
Reader Poll
How concerned are you about the current Ebola outbreak?
Connecting to poll...
Read the original article
Visit the source for the complete story.